The Australian market is experiencing turbulence, with the ASX 200 futures indicating a significant drop following the recent end of the U.S. government shutdown and ongoing economic uncertainties. Despite this volatility, penny stocks continue to capture investor interest due to their affordability and potential for growth. While often associated with smaller or newer companies, these stocks can offer intriguing opportunities when backed by strong financials and strategic positioning. In this article, we’ll explore three noteworthy penny stocks on the ASX that stand out for their potential resilience and growth prospects amidst current market conditions.
Name
Share Price
Market Cap
Financial Health Rating
Alfabs Australia (ASX:AAL)
A$0.45
A$128.96M
★★★★★☆
Dusk Group (ASX:DSK)
A$0.84
A$52.31M
★★★★★★
IVE Group (ASX:IGL)
A$3.01
A$462.61M
★★★★★☆
MotorCycle Holdings (ASX:MTO)
A$3.73
A$275.3M
★★★★★★
West African Resources (ASX:WAF)
A$3.04
A$3.47B
★★★★★★
LaserBond (ASX:LBL)
A$0.50
A$59.04M
★★★★★★
Bravura Solutions (ASX:BVS)
A$2.31
A$1.04B
★★★★★★
Praemium (ASX:PPS)
A$0.81
A$387.52M
★★★★★★
Service Stream (ASX:SSM)
A$2.25
A$1.38B
★★★★★★
GWA Group (ASX:GWA)
A$2.38
A$624.51M
★★★★★☆
Click here to see the full list of 414 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Immutep Limited is a biotechnology company focused on developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia, with a market cap of A$404.78 million.
Operations: Immutep generates revenue primarily from its immunotherapy segment, which accounts for A$5.03 million.
Market Cap: A$404.78M
Immutep Limited, a biotechnology company with a market cap of A$404.78 million, is currently pre-revenue and unprofitable, reporting A$5.03 million in revenue from its immunotherapy segment. Despite this, the company has made significant strides in clinical trials for its novel LAG-3 related immunotherapies like eftilagimod alfa (efti), which has shown promising results in treating various cancers including non-small cell lung cancer and soft tissue sarcoma. Recent positive trial data and FDA Fast Track designations highlight potential future growth avenues. Immutep’s financial stability is bolstered by sufficient cash reserves exceeding its liabilities.
ASX:IMM Debt to Equity History and Analysis as at Nov 2025
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Omni Bridgeway Limited offers dispute and litigation finance services across multiple regions including Australia, the United States, Canada, Latin America, Asia, New Zealand, Europe, the Middle East, and Africa with a market capitalization of A$449.96 million.
Operations: The company generates revenue of A$87.77 million from funding and providing services related to legal dispute resolution.
Market Cap: A$449.96M
Omni Bridgeway Limited, with a market cap of A$449.96 million, has shown significant financial improvement, reporting A$651.22 million in revenue and a net income of A$349.8 million for the year ended June 30, 2025. The company has transitioned to profitability and is trading at a favorable price-to-earnings ratio of 1.3x compared to the Australian market average of 21.1x. Its short-term assets exceed both short- and long-term liabilities, indicating strong liquidity positions. Additionally, Omni Bridgeway’s debt is well-covered by operating cash flow and its return on equity stands at an outstanding 48.3%.
ASX:OBL Financial Position Analysis as at Nov 2025
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Propel Funeral Partners Limited operates in the death care services industry across Australia and New Zealand, with a market cap of A$665.03 million.
Operations: The company generates revenue of A$225.83 million from providing death care related services across its operational regions.
Market Cap: A$665.03M
Propel Funeral Partners Limited, with a market cap of A$665.03 million, has demonstrated stable financial performance in the death care services industry. The company reported revenue of A$225.83 million and net income of A$20.4 million for the year ended June 30, 2025, reflecting improved net profit margins from the previous year. Although its return on equity is low at 5.7%, Propel’s debt level is satisfactory and well-covered by operating cash flow. Recent board changes include Naomi Edwards becoming Chair, bringing extensive governance experience to Propel as it seeks further acquisition opportunities to drive growth.
ASX:PFP Financial Position Analysis as at Nov 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:IMM ASX:OBL and ASX:PFP.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
